Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

2017/03/24 by Sunyu Kang, Kevin Gergich, Gregory M. Lubiniecki +4 · 1 citation
Medicine · Biochemistry, Genetics and Molecular Biology · #Cancer Immunotherapy and Biomarkers #CAR-T cell therapy research #Cancer Genomics and Diagnostics #Medicine #Pembrolizumab #Companion diagnostic #Monoclonal antibody #Oncology #Drug approval #Targeted therapy #Cancer #Internal medicine #Pharmacology #Antibody #Immunology #Immunotherapy #Drug

paper · pdf · doi:10.1093/annonc/mdx076

openalex publication_date 2017/03/24 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/03

Abstract

The landscape of cancer treatment has undergone a vast change over the past four decades [1,2]. Discovery of the heterogeneous molecular features of tumors and the associated microenvironment has led to the development of novel classes of targeted therapeutics [3–5], the two main types of which are small-molecule inhibitors and monoclonal antibodies (mAbs) [1–3]. These targeted drugs have furthered the development of personalized therapeutic regimens in oncology.

Citations

• The PD‐1 pathway in tolerance and autoimmunity
• The blockade of immune checkpoints in cancer immunotherapy
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
• Hallmarks of Cancer: The Next Generation
• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
• How many molecular subtypes? Implications of the unique tumor principle in personalized medicine

Cited by

• Pembrolizumab [wikipedia]